RAS阻断剂对首次心房颤动住院或心血管疾病死亡的影响在黑人和非黑人心房颤动猝死患者中并无差异。

IF 19.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of Internal Medicine Pub Date : 2024-10-01 DOI:10.7326/ANNALS-24-02170-JC

Paula Rambarat, L Kristin Newby

引用次数: 0

摘要

来源引用：Shen L, Lee MMY, Jhund PS, et al. 重新审视种族与 RAS 阻断治疗心衰的益处：随机临床试验的荟萃分析。美国医学会杂志》。2024;331:2094-2104.38809561.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

RAS blocker effects on first HF hospitalization or CV death does not differ in Black and non-Black patients with HFrEF.

Source citation: Shen L, Lee MMY, Jhund PS, et al. Revisiting race and the benefit of RAS blockade in heart failure: a meta-analysis of randomized clinical trials. JAMA. 2024;331:2094-2104. 38809561.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Internal Medicine 医学-医学：内科

CiteScore

23.90

自引率

1.80%

发文量

1136

审稿时长

3-8 weeks

期刊介绍： Established in 1927 by the American College of Physicians (ACP), Annals of Internal Medicine is the premier internal medicine journal. Annals of Internal Medicine’s mission is to promote excellence in medicine, enable physicians and other health care professionals to be well informed members of the medical community and society, advance standards in the conduct and reporting of medical research, and contribute to improving the health of people worldwide. To achieve this mission, the journal publishes a wide variety of original research, review articles, practice guidelines, and commentary relevant to clinical practice, health care delivery, public health, health care policy, medical education, ethics, and research methodology. In addition, the journal publishes personal narratives that convey the feeling and the art of medicine.